ReviewCancer communications (London, England)2019

China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.

Ming Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.